Pharnext announces the establishment by Néovacs of a management trust to manage the Pharnext securities issued as well as the rights and obligations of Néovacs under the financing agreement signed on September 30, 2022 – 10/31/2022 at 6:30 p.m.

PARIS, France, October 31, 2022 at 6:30 p.m. (CET) – Pharnext SA (FR0011191287 – ALPHA) (the “Company”), an advanced clinical-stage biopharmaceutical company developing new therapies for neurodegenerative diseases with no satisfactory therapeutic solution, announces today today the conclusion of an agreement with the company Néovacs for the establishment by Néovacs of a management trust (the “Trust”), having as trustee the company Equitis Gestion (the “Trustee”), to exercise all the rights and honor all of the latter’s obligations as well as manage the securities issued by Pharnext for the benefit of Neovacs and the Trust respectively under the OBSA Agreement signed on September 30, 2022 between Pharnext and Neovacs (the “Trust Agreement”).